News

Luminoah closes $6M Series A round

Charlottesville medical device company Luminoah Inc. has closed a $6 million Series A round it says it will use to complete the development of its mobile feeding tube device that collects data.

The round was led by Charlottesville’s Fry’s Path Capital and included participation from Arlington’s Sands Capital, Charlottesville’s CAV Angels, Virginia Beach’s 757 Angels and Richmond’s Virginia Venture Partners — the equity investment arm of the Virginia Innovation Partnership Corp.

Luminoah, which took top honors at the Light House Labs’ Demo Day competition last month, says its device lets patients to keep a more mobile lifestyle while on a feeding tube. Its data-tracking features also allow remote patient monitoring.

CEO Neal Piper started the company after his young son was diagnosed with cancer and required a constraining feeding tube.

“It’s just a no-brainer to let a kid be active while you pump nutrition into their stomach,” Piper told Richmond Inno last month.

Piper said the goal is to apply for Food and Drug Administration approval in 2024. Luminoah wants to go after the pediatric home health care market initially, but also seeks to move into senior and rehabilitation markets. The company says the enteral feeding technology market is worth about $12 billion and that half-a-million children could benefit from its product.

Learn more here.

Recent News

09/17/2026

Rivanna Announces New CMS Procedure Code for Computer-aided Neuraxial Guidance

RIVANNA®, developer of AI-enabled clinical decision-support solutions, today announced that the Centers for Medicare & Medicaid Services (CMS) has established ICD-10-PCS code XEZU3HC, effective for inpatient discharges beginning October 1, 2026. The code identifies computer-aided intraprocedural navigation in the spinal canal using ultrasound imaging with continuous needle tracking via a percutaneous approach during neuraxial anesthesia.

09/17/2026

From Lab to Three Continents: Agrospheres and FMC Corporation Advance Bioinsecticide Pipeline into Global Field Trials

AgroSpheres, a biotechnology company pioneering breakthroughs in sustainable crop protection and FMC Corporation (NYSE: FMC), a global leader in agricultural sciences, today announced a significant advancement in its ongoing collaboration. Two proprietary RNA-based biomolecule candidates from AgroSpheres’ pipeline are now entering global field trial development, marking the transition from discovery into real-world testing across three

09/15/2026

Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz” or the “Company”) today announced the successful completion of its acquisition of privately-held Actio Biosciences, Inc. (“Actio”) for $820 million upfront. Actio is now a wholly-owned subsidiary of Jazz. “ABS-1230 holds the promise of being a transformative, first-in-class therapy for individuals living with KCNT1-related epilepsy,” said Renee Gala, president and